Business Context and Reporting Period
This Form 6-K filing by Celsus Therapeutics PLC (note: metadata references Akari Therapeutics, but the filing text identifies Celsus Therapeutics) is dated December 11, 2013. The report discloses material corporate governance changes involving senior executive and board resignations.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed is a severance payment of $232,600 made to a former executive.
Material Changes
- Executive Resignation: Saul Yedgar resigned as Chief Scientific Officer on December 8, 2013. He remains a member of the board of directors and is a principal shareholder.
- Board Resignation and Severance: Yuval Cohen, former President, resigned from the board of directors on December 10, 2013. The resignation was without disagreement.
- Compensation Settlement: Mr. Cohen received a gross payment of $232,600 representing deferred base compensation for 42 months of service, accompanied by mutual releases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of general business risks. The primary contingency noted is the completion of the employment termination agreement with Mr. Cohen.
Investor Verification Checklist
- Verify the current status of the Chief Scientific Officer role following Dr. Yedgar's resignation.
- Confirm the composition of the Board of Directors following the departure of Mr. Cohen.
- Review the impact of the $232,600 severance payment on the company's immediate cash position.
- Clarify the relationship between the metadata name (Akari Therapeutics) and the filing entity (Celsus Therapeutics).